Purpose: Hypoxic-ischemic brain injuries influence the mechanisms of signal transduction, including mitogen-activated protein kinase (MAPK) that regulates gene expression through transcription factor activity. Several attempts have been made to use bee venom (BV) to treat neurological diseases. However, limited data are available for brain injuries such as neonatal hypoxic-ischemic encephalopathy (HIE) and neurodegenerative disorders. The purpose of this study was to investigate the neuroprotective effects of BV by determining the expression of activated MAPK pathways. Methods: We examined activation and cell viability in hypoxia (1% O 2 , 5% CO 2 , 94% N 2 ) in low glucose-treated (H+low G) neuronal cells and astrocytes in the presence and absence of BV. After they were subjected to hypoxic conditions and treated with low glucose, the cells were maintained for 0, 6, 15, and 24 h under normoxic conditions. Results: Extracellular-signal-regulated kinases 1/2 (ERK1/2), p38 MAPK, and stressactivated protein kinases (SAPK)/Jun amino-terminal kinases (JNK) were activated in H+low G conditions. Particularly, phosphorylation of ERK1/2 was maximized 6 h after exposure to H+low G condition. BV specifically inhibited the phosphorylation of ERK1/2. However, BV had no effect on p38 MAPK or SAPK/JNK. In addition, BV improved neuronal cell and astrocytes viability following exposure to H+low G. Conclusion: ERK inactivation is known to mediate protective effects in hypoxic brain injury. Taken together, these results suggest that treatment with BV may be helpful in reducing hypoxic injury in neonatal HIE through the ERK signaling pathway.
INTRODUCTION
Bee venom (BV) has been used for medical purposes around the world, particularly in oriental countries. Recently, the Food and Drug Administration (FDA) approved the use of BV for allergy desensitization 1) . BV has many biologic activities including anti-inflammatory, anti-neurotoxic, anti-bacterial, antialler gic, and anti-hypertensive effects and regulatory functions in the autonomic nervouse system [2] [3] [4] . BV has been used to treat rheumatioid arthritis, Parkinson's disease, multiple sclerosis, neuro-muscular pain syndrome, skin disease, and immune dis ease 5, 6) . BV contains various peptides, enzymes, and non-peptide components. BV peptides include melittin, apamin, mast cell de granulation peptide and adolapin.
The non-peptide components of BV consist of histamine, dopamine, noradrenaline, carbohydrates and some lipids. BV enzymes include phospholipase A2 (PLA2), hyaluronidase, acid phosphomonoesterase, α-d-glucosidase, and lypophospholipase 7) . Hypoxic-ischemic brain injury is a pathological insult that resulting in energy failure caused by low arterial oxygen ten sion and inadequate blood flow 8, 9) . The cerebral neuronal response to hypoxia results in a massive release of glutamate followed by calcium influx, inflammatory cytokine release, and reactive oxygen species (ROS) formation 10, 11) . These condi tions cause a critical shortage of energy (energy crisis). There is growing evidence that the mechanisms underlying the neu ronal damage caused by hypoxia involve the activation of multiple intracellu lar signal transduction pathways 12, 13) . These signal transduction pathways modulate multiple kinases including protein kinase C and mitogen activated protein kinase (MAPK) 8) . The MAPK family is mainly composed of key regulatory pro teins that con trol inflammation and physiological processes. These pro tein are regulated by phosphorylation cascades 14, 15) , and phos phorylation plays a crucial role in their regulatory func tion 16) .
In mammals, there are at least three distinct groups of MAPKs, including extracellular-signal-regulated kinases 1/2 (ERK1/2), stress-activated protein kinases (SAPK)/Jun amino-terminal kinases (JNK) and p38 MAPK. MAPKs transduce a wide ran ge of extracellular stimuli into various cellular res ponses by producing changes in the transcription of key genes. They also targets protein expression and play an important role in regulating neuronal death after hypoxia 17, 18) . ERKs are widely expressed in nervous tissue and are associated with cell survival 19) . They are activated by growth factors, intracellular calcium increases, glutamate receptor stimulation and mitogenic stimuli, and are involved in cell proliferation, division, development and differentiation 20) . On the other hand, SAPK/JNK and p38 MAPK are activated in response to various stresses such as hyperosmosis, oxidative stress, ultraviolet radiation, inflammatory cytokines, DNA damage and heat shock proteins. Through modulation of transcriptional factors expression, they are involved in apoptosis, inflamma tion, cell cycle arrest, and cell differentiation 19, 21) .
BV exerts anti-inflammatory effects by inhibiting nuclear factor kappa-B (NF-κB) activation and modulating the expression of various inflammatory cytokines such as tumor necro sis factor alpha 2, 3) . BV is known to downregulate inducible nitric oxide synthase and cyclooxygenase-2, possibly through NF-κB and MAPK activation in neuronal and glial cells 3, 22) . Additionally, melittin, a major component of BV, has anti-inflamma tory eff ects by decreasing the expression of inflammatory cytokines through the regulation of NF-κB and MAPK signaling pathways 23) . Finally, prion protein-mediated activation of p38 MAPK and cleaved caspases and the inactivation of Akt are blocked by BV PLA2 24) .
Limited data are available for brain injuries such as neonatal hypoxic-ischemic encephalopathy, neurodegenerative disorders and excitotoxicity. Furthermore, it is not clearly understood whether BV can function as a neuroprotective agent, and whether it has effects on members of MAPK involved in the neuroprotection of hypoxia-induced injuries in neuronal model systems. Therefore, the aim of the present study was to investigate whether BV could reduce cell injury following ex posure to hypoxic and low-glucose condition (H+low G). This study also evaluated whether MAPK pathways, including ERK, p38 MAPK and SAPK/JNK, are associated with the mecha nisms of the neuroprotective effects of BV.
MATERIALS AND METHODS

Materials (Chemicals and Reagents)
BV was obtained from the National Institute of Agricultural 
Cortical Neuronal Cell and Astrocyte Cultures
This study was performed in accordance with the approved animal use guidelines of the Catholic University of Daegu. Culture of cortical neuronal cells from rat embryos followed the Bre wer method 25) . To obtain primary cultured cortical neurons, the cortex was dissected from an embryonic 14-day-old (E14, Cells were seeded at a density of 2×10 6 cells/mm 2 onto culture dish precoated with 50 μg/mL poly-D-lysine. Cultures were maintained in Neurobasal media at 37°C in 95% humidified air with 5% CO2.
Cortical astrocytes used for the primary cultures were prepared from the cerebral cortices of 1-day-old Sprague Dawley rats (both sexes) as previously described 26) . In summary, the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra zolium bromide (MTT) Assay
An MTT assay was used to evaluate cell viability and cell growth. Cells were plated into 96-well cell culture plates. Cells were incubated in the presence of 0.5 mg/mL MTT. After 3-4
hours of incubation at 37˚C in the dark, the medium was removed and the formazan dye was extracted using 100 µL of the lysing buffer (1:1 dimethyl sulfoxide:95% ethanol). Absorbance of the samples was determined at 540 nm using a microtiter plate enzyme-linked immunosorbent assay reader. The amount of formazan produced was proportional to the number of live and metabolically active cells.
Protein Extraction for Neuronal Cells and Astrocytes
Growth medium from the cells was removed by aspiration.
Cells were washed with PBS to remove residual medium. Cells were extracted with radioimmunoprecipitation assay lysis buffer (Rockland, Gilbertsville, PA, USA). After incubation for 5 min on ice, total cell extracts were centrifuged at 12,000 rpm at 4˚C for 10 min. Protein-containing supernatants were collected.
Proteins were quantified using a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) by taking spectrophotometric readings at 540 nm. Concentrations were estimated against a standard curve of bovine serum albumin (BSA).
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot Analysis
A total of 30 μg of protein from each sample was loaded for 12% SDS-PAGE after denaturing in 5 x SDS gel-loading buffer 
Statistics Analysis
Data were analyzed using the SPSS version 22 (SPSS Inc., Chicago, IL, USA) statistical analysis package. Examined data were assessed using the t-test, and ANOVA. In each test, the data were expressed as the mean±standard deviation using Excel 2007. A P-value lower than 0.05 was as considered statistically significant.
RESULTS
Optimal Concentration of BV in Neuronal Cells and As trocytes
To find the optimum concentration of BV, cell viabilities were 0.2 µg/mL, 104±1%; 0.4 µg/mL, 107±2%; 0.6 µg/mL, 98±5%; 0.8 µg/mL, 86±4%; 1.0 µg/mL, 83±3%; 3.0 µg/mL, 72±5%). At concentra tions above 5 μg/mL, BV significantly caused a de crease in as trocyte viability (P<0.01, n=4, Figure 1B ; 0.0 µg/mL, 100±3%; 0.8 µg/mL, 104±4%; 1.5 µg/mL, 107±4%; 2.5 µg/mL, 112±2%; 5.0 µg/mL, 92±4%; 7.0 µg/mL, 77±3%; 9.0 µg/mL, 57±5%). These relative cell viabilities of neuronal cells and astrocytes were 0.4 and 2.5 μg/mL, respec tively. Thus, all experiments in the present study were done using these optimum concen trations of BV.
Effect of BV Pretreatment on Activation of MAPKs in Neuronal Cells Following Exposure to H+low G Condition
The 
Effect of BV on Activation of MAPKs Following Exposure to H+low G Conditions in a Astrocytes
The time courses of MAPK family activation was determined in astrocytes the same way as in the neuronal cells ( 
Effect of BV on Neuronal Cell Viability
Viability of cultured neuronal cells was measured by MTT assay (Figure 4) . 
Effect of BV on Astrocyte Viability
Astrocyte 
DISCUSSION
The present study demonstrated that BV pretreatment improves cell viability in neuronal cells and astrocytes exposed to H+low G conditions. BV inhibited the phosphorylation of ERK1/2 in both neuronal cells and astrocytes following exposure to H+low G conditions. ERK1/2, p38 MAPK, and SAPK/ JNK were significantly upregulated in H+low G conditions in both neuronal cells and astrocytes, which is consistent with previously reported findings in hypoxic injuries 14, 27) . However, there were some differences in time taken to achieve maximal activation after hypoxic insult among MAPKs.
In neuronal cells, phosphorylation of ERK was increased following exposure to H+low G conditions, reached peak level 6 h following exposure, and showed the lowest levels 15 h following exposure. In astrocytes, phosphorylation of ERK was increased following exposure to H+low G conditions, reached peak level 6 h following exposure, and then gradually decreas- ed until the 24 h timepoint. It has been reported that maximal ERK activation occurs several hours after hypoxic insult 9, 28, 29) .
The results obtained from this study are consistent with other recent reports.
The phosphorylation level of p38 MAPK and SAPK/JNK reached a maximum just after hypoxic insult in neuronal cells and astrocytes. These data are consistent with previously reported findings 12, 21) . These findings suggest that activation of p38 MAPK and SAPK/JNK after hypoxic insult may be an early and transient event.
Several studies have demonstrated that MAPKs are activated after hypoxic insult 12, 25, 26, 30) . There is increasing evidence that inhibition of MAPK pathways can alter the outcome of HI brain injury by regulating cell death or survival in animal models 11, 31) .
However, previous reports show conflicting evidence regarding the role of the MAPK pathways (particularly ERKs) in cell survival or neuroprotection under conditions hypoxia or neuronal injury 32) .
ERKs are important regulators of neuronal function 33) . Activation of ERK has been reported to contribute to neuronal death in some models of neurotoxicity 3, 15) . The mechanisms that mediate these deleterious effects of ERK activation have not been fully elucidated. They may include the release of excitotoxic glutamate by ERK activation 34) . It has been reported that ERK activation is prominently involved in neurodegeneration, such as ischemia in animal models 35) . Prolonged ERK stimula tion ultimately promotes neuron degeneration through plasma membrane damage via caspase-dependent or -independent mechanisms 35) . Prolonged activation of ERK is also associated with neuronal apoptotic cell death in response to ROS production in the hippocampal cell line HT22 36) . Furthermore, it has been demonstrated that inhibition of ERK activation protects against cell damage after HI exposure 9, 20, 27, 29) .
However, ERK signaling has also been reported to be involved in neurogenesis. It can induce tolerance to HI injury in brains of newborn rats 15) . In addition to an inflammatory response, the brain may respond to hypoxia by neurogenesis and release of growth factors. For example, nerve growth factor can induce the ERK1/2 signaling pathway 37) . Several reports have suggested that the ERK1/2 signaling pathway can increase cell survival through the activation of cAMP response element-binding protein (CREB) 15, 35, 36) . ERK1/2 activation has been observed in the ischemic necrotic core shortly after HI neuro nal injury in neonatal rats 33) . It has been reported that differ ential ERK1/2 activation at later time points after HI exposure is also found in different cell types (neuronal cells, microglial cells, astrocytes and oligodendrocytes) in the penumbra area, suggesting a dual role of ERK1/2 in cell survival and/or cell death 15) . These reports suggest that the neuroprotective role of ERK1/2 may depend on the duration and timing of its acti vation 33) . A recent study has shown that the caspase-dependent component of cell death after neonatal HI does not peak until 12-24 h after injury 38) . This finding suggests that there is a possible therapeutic window in which effects of ERK activation on both transcriptiondependent and -independent mecha nisms could influence cell survival.
Recently, BV has been increasingly implicated in modulating intracellular signaling pathways including MAPKs 2, 6, 13, 21, 39) . In this study, BV pretreatment inhibited the H+low G-induced ERK phosphorylation. However, it did not affect the phosphorylation of JNK or p38 MAPKs in astrocytes or neuronal cells. This is in some contradiction to a previous report, in which they showed that BV inhibited the early phosphorylation of ERK, p38 MAPK, and JNK following glutamate-induced toxicity 3) .
According to their report, JNK and p38 MAPK were associated with the neuroprotective function of BV.
This study showed that BV inhibited early JNK and p38
phosphorylation at 0 h but this did not show statistical significance. Further studies are needed to clarify this mechanisms of BV. In an earlier report, the inhibition of the p38 MAPK has no influence on cell proliferation determined 6 d after ischemia.
Early blockage of p38 phosphorylation in activated microglial cells could influence neurogenesis 11) . Therefore, these findings led to the suggestion that the functional relevance of MAPK activation may depend upon the cell type, the nature of the stimulus, and the environmental conditions 40) .
The present study showed that the neuronal cell and astrocyte injuries were reduced in the BV+H+low G group. When 
